Retention of Locally Injected Human IPS Cell-derived Cardiomyocytes into the Myocardium Using Hydrolyzed Gelatin

Overview

Journal Sci Rep

Date 2025 Feb 7

PMID 39920228

Authors

Jun Iida

Kazuki Kotani

Kozue Murata

Keisuke Hakamada

Wusiman Maihemuti

Yoshinobu Mandai

Yosuke Hiraoka

Kenji Minatoya

Hidetoshi Masumoto

Affiliations

Soon will be listed here.

Abstract

This study explored the impact of hydrolyzed gelatin (HG) concentration on the retention and therapeutic efficacy of human iPS cell-derived cardiomyocytes (hiPSC-CMs) when injected into the myocardium. The solubility of HG allows precise control over its concentration, influencing the distribution and leakage of injected solutions, which may affect therapeutic outcomes. Using both ex vivo and in vivo rat models, we investigated how varying HG concentrations affect the retention of solution and diffusion within the myocardium. In ex vivo static rat hearts, 10% HG minimized leakage but allowed significant diffusion. However, in pulsating in vivo hearts, 20% HG provided the best retention. In a rat myocardial infarction model, hiPSC-CMs suspended in 20% HG resulted in the highest cell retention. Echocardiogram showed a significant increase in the ejection fraction two weeks after transplantation compared to before transplantation. Additionally, cardiac magnetic resonance imaging (MRI) revealed that the ejection fraction was significantly higher than that of the sham group four weeks after transplantation. These findings suggest that optimizing HG concentration is crucial for enhancing the retention and therapeutic efficacy of hiPSC-CM transplants in treating heart disease.

References

Shiao W, Wu T, Kuo C, Tsai Y, Tsai M, Hong Y . Physicochemical and Antioxidant Properties of Gelatin and Gelatin Hydrolysates Obtained from Extrusion-Pretreated Fish ( sp.) Scales. Mar Drugs. 2021; 19(5). PMC: 8156103. DOI: 10.3390/md19050275. View

Kotani K, Ngako Kadji F, Mandai Y, Hiraoka Y . Backflow reduction in local injection therapy with gelatin formulations. Drug Deliv. 2024; 31(1):2329100. PMC: 10962293. DOI: 10.1080/10717544.2024.2329100. View

Funakoshi S, Miki K, Takaki T, Okubo C, Hatani T, Chonabayashi K . Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes. Sci Rep. 2016; 6:19111. PMC: 4705488. DOI: 10.1038/srep19111. View

Konegawa Y, Kuwahara T, Jo J, Murata K, Takeda T, Ikeda T . Pioglitazone-incorporated microspheres targeting macrophage polarization alleviates cardiac dysfunction after myocardial infarction. Eur J Cardiothorac Surg. 2022; 62(5). DOI: 10.1093/ejcts/ezac414. View

Padilla C, Quero F, Pepczynska M, Diaz-Calderon P, Acevedo J, Byres N . Understanding the Molecular Conformation and Viscoelasticity of Low Sol-Gel Transition Temperature Gelatin Methacryloyl Suspensions. Int J Mol Sci. 2023; 24(8). PMC: 10139010. DOI: 10.3390/ijms24087489. View

Tilokee E, Latham N, Jackson R, Mayfield A, Ye B, Mount S . Paracrine Engineering of Human Explant-Derived Cardiac Stem Cells to Over-Express Stromal-Cell Derived Factor 1α Enhances Myocardial Repair. Stem Cells. 2016; 34(7):1826-35. DOI: 10.1002/stem.2373. View

Han M, Jeon J, Shin J, Kim H, Lee J, Seo C . Intramyocardial delivery of human cardiac stem cell spheroids with enhanced cell engraftment ability and cardiomyogenic potential for myocardial infarct repair. J Control Release. 2021; 336:499-509. DOI: 10.1016/j.jconrel.2021.06.040. View

Shahim B, Kapelios C, Savarese G, Lund L . Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev. 2023; 9:e11. PMC: 10398425. DOI: 10.15420/cfr.2023.05. View

Ogasawara T, Okano S, Ichimura H, Kadota S, Tanaka Y, Minami I . Impact of extracellular matrix on engraftment and maturation of pluripotent stem cell-derived cardiomyocytes in a rat myocardial infarct model. Sci Rep. 2017; 7(1):8630. PMC: 5561148. DOI: 10.1038/s41598-017-09217-x. View

10.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

11.

Masumoto H, Sakata R . Cardiovascular surgery for realization of regenerative medicine. Gen Thorac Cardiovasc Surg. 2012; 60(11):744-55. DOI: 10.1007/s11748-012-0139-7. View

12.

Eschenhagen T, Ridders K, Weinberger F . How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol. 2021; 163:106-117. DOI: 10.1016/j.yjmcc.2021.10.005. View

13.

Matsuo T, Masumoto H, Tajima S, Ikuno T, Katayama S, Minakata K . Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells. Sci Rep. 2015; 5:16842. PMC: 4653625. DOI: 10.1038/srep16842. View

14.

Landini G, Martinelli G, Piccinini F . Colour deconvolution: stain unmixing in histological imaging. Bioinformatics. 2020; 37(10):1485-1487. DOI: 10.1093/bioinformatics/btaa847. View

15.

Lukin I, Erezuma I, Maeso L, Zarate J, Federico Desimone M, Al-Tel T . Progress in Gelatin as Biomaterial for Tissue Engineering. Pharmaceutics. 2022; 14(6). PMC: 9229474. DOI: 10.3390/pharmaceutics14061177. View

16.

Laflamme M, Gold J, Xu C, Hassanipour M, Rosler E, Police S . Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol. 2005; 167(3):663-71. PMC: 1698736. DOI: 10.1016/S0002-9440(10)62041-X. View

17.

Kitahata S, Mandai M, Ichikawa H, Tanaka Y, Senba T, Kajita K . Investigation of the effectiveness of gelatin hydrolysate in human iPS-RPE cell suspension transplantation. Regen Ther. 2024; 25:238-249. PMC: 10825282. DOI: 10.1016/j.reth.2023.12.016. View

18.

Davidson S, Padro T, Bollini S, Vilahur G, Duncker D, Evans P . Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart. Cardiovasc Res. 2021; 117(10):2161-2174. PMC: 8344830. DOI: 10.1093/cvr/cvab200. View

19.

Osada H, Kawatou M, Fujita D, Tabata Y, Minatoya K, Yamashita J . Therapeutic potential of clinical-grade human induced pluripotent stem cell-derived cardiac tissues. JTCVS Open. 2022; 8:359-374. PMC: 9390608. DOI: 10.1016/j.xjon.2021.09.038. View

20.

Shalabi A, Kachel E, Kassif Y, Faqeeh M, Sergey P, Sternik L . Unusual complications following left ventricular assisted device implantation: case series. J Cardiothorac Surg. 2021; 16(1):70. PMC: 8025327. DOI: 10.1186/s13019-021-01445-7. View